TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02170259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The suboccipital technique
Description: The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The articulatory technique
Description: The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
Study: NCT04521686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Oral LY3410738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous durvalumab
Study: NCT02170259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined treatment
Description: Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
Study: NCT00644566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Care
Description: A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
Study: NCT04373694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginoscopy
Description: vaginal distension with hysteroscope for hysteroscopy morcellation (without speculum or tenaculum forceps)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard hysteroscopy
Description: speculum, paracervical block before hysteroscopy morcellation
Study: NCT00776009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
Description: 10 mg and/or 20 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
Description: 10 mg and/or 20 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02954237

Intervention type: DEVICE
Intervention: AMPLATZER™ Cardiac Plug
Description: The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
Study: NCT02663674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
Study: NCT01823185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor or prasugrel
Description: ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
Study: NCT04676282

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
Study: NCT01465152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Adminstered orally during the three main meals for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Adminstered orally during the three main meals for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Administered orally before the three main meals for 24 weeks
Study: NCT04676282

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
Study: NCT04303013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
Study: NCT00542490

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal Cuff Brachytherapy
Description: Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
Study: NCT01262638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 daily for 12 weeks
Study: NCT04676282

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
Study: NCT01465152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Administered orally before the three main meals for 24 weeks
Study: NCT04676282

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.

Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
Study: NCT00688753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study: NCT01730391

Intervention type: OTHER
Intervention: Data collection
Description: Collection of demographic data and vaccination history

Intervention type: OTHER
Intervention: CSF samples testing
Description: CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
Study: NCT02256904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomical TKA
Description: Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical TKA
Description: Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
Study: NCT01892293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with NY-ESO-1c259-modified T cells
Description: An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given.
Study: NCT01713686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT01853761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise after
Description: Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exercise after
Description: Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise after
Description: Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise after
Description: Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise at same time
Description: Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneos
Description: Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneos
Description: Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneos
Description: Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
Study: NCT01262638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 daily for 12 weeks
Study: NCT01853761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneos
Description: Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous microcurrent
Description: Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-10Hz
Description: microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-10Hz
Description: microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-10Hz
Description: microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-50Hz microcurrent
Description: microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
Study: NCT03940612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: STP4 (product with probiotics)
Description: STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (product without probiotics)
Description: Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
Study: NCT02974166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Group
Description: Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Group
Description: Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine Hydrochloride
Description: The medication was prescribed by the dentist as muscle relaxer if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine Hydrochloride
Description: The medication was prescribed by the dentist as muscle relaxer if necessary.
Study: NCT02362217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv
Description: Genetic vaccine against HIV-1 infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv
Description: Genetic vaccine against HIV-1 infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: Genetic vaccine against HIV-1 infection
Study: NCT01566890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson infusion with contrast-enhanced ultrasound
Description: Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced ultrasound
Description: Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced ultrasound
Description: Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced ultrasound
Description: Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later

Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced ultrasound
Description: Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
Study: NCT03315065

Intervention type: DRUG
Group type: OTHER
Intervention: Perfluorinated Gas/Oxygen Mixture
Description: 19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, \< 1 hour
Study: NCT02376309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inactivity
Description: Inactivity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inactivity
Description: Inactivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND
Description: 1 nandrolone decanoate injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leu
Description: Leucine supplements
Study: NCT04176952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-A
Description: * nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG
Description: * nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel).
Study: NCT01933997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metadoxine (MG01CI )
Study: NCT02447666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study: NCT04346914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
Description: ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w